The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Inavolisib combination demonstrates 57% PFS in breast cancer indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer, demonstrated positive results.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Columvi combination extends OS in transplant-ineligible R/R DLBCL in phase III trial

In the phase III STARGLO study of Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy, the Columvi regiment extended overall survival.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account